Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
<<<
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More